{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:12:44Z","timestamp":1780758764209,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1492,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/jto.0b013e31822adb19","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T21:06:56Z","timestamp":1317762416000},"page":"1915-1922","source":"Crossref","is-referenced-by-count":13,"title":["Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Christopher G.","family":"Azzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Subzwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.M.","family":"Sirotnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31822adb19_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0079-6603(01)67027-2","article-title":"Molecular and cellular biology of the human reduced folate carrier","volume":"67","author":"Matherly","year":"2001","journal-title":"Prog Nucleic Acid Res Mol Bio"},{"key":"10.1097\/JTO.0b013e31822adb19_bib3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1097\/JTO.0b013e31822adb19_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","article-title":"Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers","volume":"64","author":"Izbicka","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-Cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib6","first-page":"508","article-title":"Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies","volume":"11","author":"Molina","year":"2008","journal-title":"IDrugs"},{"key":"10.1097\/JTO.0b013e31822adb19_bib7","first-page":"3493","article-title":"Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate","volume":"6","author":"Krug","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822adb19_bib8","first-page":"2072","article-title":"10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer","volume":"9","author":"Krug","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822adb19_bib9","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","article-title":"A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31822adb19_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/sonc.2002.37465","article-title":"Pemetrexed safety and dosing strategy","volume":"29","author":"Niyikiza","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e31822adb19_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl","key":"10.1097\/JTO.0b013e31822adb19_bib13","first-page":"489s","article-title":"Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC","volume":"29","author":"Patel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2009.23.6406","article-title":"Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426","volume":"28","author":"Adjei","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31822adb19_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415322565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415322565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T02:17:21Z","timestamp":1560737841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415322565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1556086415322565"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31822adb19","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}